Andreas Rosenwald Selected Research

carboxyl radical (COO-)

9/2018	Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining.
8/2017	Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
2/2014	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.
11/2011	The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
6/2011	Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas Rosenwald Research Topics

Disease

119	Neoplasms (Cancer) 05/2022 - 04/2002
54	Lymphoma (Lymphomas) 01/2022 - 12/2003
48	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2022 - 06/2002
32	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 02/2021 - 11/2005
29	B-Cell Lymphoma (Lymphoma, B Cell) 04/2021 - 12/2002
20	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 05/2002
19	Disease Progression 12/2021 - 09/2004
19	Multiple Myeloma 10/2021 - 01/2012
15	Burkitt Lymphoma (Burkitt's Lymphoma) 02/2020 - 06/2006
14	Hodgkin Disease (Hodgkin's Disease) 06/2022 - 11/2004
13	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2022 - 06/2003
12	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2021 - 04/2002
11	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 06/2009
8	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2016 - 06/2003
7	Carcinogenesis 04/2022 - 04/2009
7	Genetic Translocation (Chromosomal Translocation) 12/2016 - 12/2002
6	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 08/2010
6	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 11/2021 - 06/2009
6	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 01/2015
5	Infections 01/2021 - 06/2003
5	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2012
5	Adrenocortical Carcinoma 12/2018 - 11/2015
4	Carcinoma (Carcinomatosis) 01/2022 - 08/2004
4	Inflammation (Inflammations) 01/2021 - 10/2010
4	Leukemia 05/2017 - 06/2004
3	Adenoma (Adenomas) 01/2022 - 03/2012
3	Breast Neoplasms (Breast Cancer) 01/2021 - 03/2008
3	Melanoma (Melanoma, Malignant) 01/2019 - 08/2013
2	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 11/2013

Drug/Important Bio-Agent (IBA)

41	Proteins (Proteins, Gene)FDA Link 12/2022 - 04/2002
21	Biological ProductsIBA 04/2022 - 05/2002
19	Biomarkers (Surrogate Marker)IBA 04/2022 - 07/2006
19	Rituximab (Mabthera)FDA Link 07/2021 - 01/2011
17	DNA (Deoxyribonucleic Acid)IBA 10/2021 - 06/2002
14	ParaffinIBA 11/2017 - 10/2008
12	MicroRNAs (MicroRNA)IBA 12/2022 - 09/2008
12	Messenger RNA (mRNA)IBA 11/2021 - 02/2003
12	RNA (Ribonucleic Acid)IBA 10/2021 - 05/2005
12	Vincristine (Oncovin)FDA LinkGeneric 04/2021 - 12/2011
12	Phosphotransferases (Kinase)IBA 01/2020 - 09/2005
11	AntigensIBA 01/2022 - 05/2002
11	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2021 - 12/2011
11	Prednisone (Sone)FDA LinkGeneric 01/2021 - 12/2011
11	Cyclin D1IBA 01/2021 - 02/2003
11	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 12/2011
11	Formaldehyde (Formol)FDA Link 11/2017 - 10/2008
9	Pharmaceutical PreparationsIBA 04/2022 - 09/2004
9	AntibodiesIBA 01/2022 - 04/2009
7	CyclinsIBA 01/2021 - 12/2005
7	Protein Isoforms (Isoforms)IBA 02/2017 - 06/2007
7	Complementary DNA (cDNA)IBA 01/2013 - 07/2003
7	NF-kappa B (NF-kB)IBA 05/2008 - 12/2002
6	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 10/2021 - 06/2003
6	ibrutinibIBA 02/2021 - 09/2014
6	Immunoglobulin M (IgM)IBA 01/2019 - 04/2004
6	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 12/2002
6	Anaplastic Lymphoma KinaseIBA 05/2014 - 04/2002
5	Etoposide (VP 16)FDA LinkGeneric 04/2021 - 11/2011
5	CytokinesIBA 01/2020 - 02/2003
5	carboxyl radical (COO-)IBA 09/2018 - 06/2011
4	Keratins (Keratin)IBA 01/2022 - 01/2012
4	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 10/2013
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 11/2011
4	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 11/2011
4	Monoclonal AntibodiesIBA 01/2021 - 08/2013
4	LigandsIBA 01/2021 - 11/2005
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 07/2019 - 11/2004
3	Mitogen-Activated Protein KinasesIBA 05/2022 - 10/2010
3	Chemokine ReceptorsIBA 01/2022 - 04/2015
3	Lenalidomide (CC 5013)FDA Link 01/2021 - 09/2016
3	AutoantigensIBA 01/2021 - 11/2015
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020 - 07/2007
3	Peptides (Polypeptides)IBA 01/2020 - 11/2013
3	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2019 - 03/2009
3	ChemokinesIBA 10/2018 - 03/2009
3	Endoplasmic Reticulum Chaperone BiPIBA 09/2016 - 01/2013
3	Glucose (Dextrose)FDA LinkGeneric 09/2016 - 08/2013
3	Bortezomib (Velcade)FDA Link 09/2016 - 03/2009
3	Transcription Factors (Transcription Factor)IBA 09/2015 - 05/2005
3	Cisplatin (Platino)FDA LinkGeneric 01/2014 - 03/2008
3	Tyrosine (L-Tyrosine)FDA Link 01/2013 - 12/2010
3	Cyclin D2IBA 11/2009 - 02/2004
3	Indicators and Reagents (Reagents)IBA 01/2007 - 12/2005
2	Cre recombinaseIBA 12/2022 - 10/2010
2	Insulin (Novolin)FDA Link 12/2022 - 01/2022
2	Tetracycline (Achromycin)FDA LinkGeneric 12/2022 - 05/2009
2	Gemcitabine FDA Link 01/2022 - 11/2017
2	Brentuximab VedotinIBA 01/2022 - 01/2014
2	NivolumabIBA 01/2022 - 01/2020
2	68Ga-pentixaforIBA 01/2022 - 11/2017
2	obinutuzumabIBA 01/2022 - 04/2020
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2021 - 01/2021

Therapy/Procedure

52	Therapeutics 10/2022 - 02/2003
16	Drug Therapy (Chemotherapy) 04/2021 - 06/2002
8	Stem Cell Transplantation 04/2021 - 11/2011
6	Immunotherapy 10/2021 - 01/2013
4	Aftercare (After-Treatment) 10/2021 - 05/2017
3	Cell Transplantation 01/2021 - 01/2013
3	Radiotherapy 01/2021 - 11/2019
3	Salvage Therapy 01/2020 - 11/2011